Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short-term Investments (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Short-term Investments for 12 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 95.29% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 95.29% year-over-year, with the annual reading at $2.4 million for FY2025, 95.29% down from the prior year.
  • Short-term Investments for Q4 2025 was $2.4 million at Theravance Biopharma, roughly flat from $2.4 million in the prior quarter.
  • The five-year high for Short-term Investments was $96.0 million in Q1 2021, with the low at $2.4 million in Q4 2025.
  • Average Short-term Investments over 5 years is $53.4 million, with a median of $55.2 million recorded in 2023.
  • The sharpest move saw Short-term Investments soared 114.52% in 2023, then plummeted 96.49% in 2025.
  • Over 5 years, Short-term Investments stood at $83.5 million in 2021, then tumbled by 64.9% to $29.3 million in 2022, then surged by 114.52% to $62.9 million in 2023, then fell by 19.61% to $50.6 million in 2024, then plummeted by 95.29% to $2.4 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $2.4 million, $2.4 million, and $56.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.